Oncology & Hematologic Malignancies

 A breakthrough in targeted therapeutics for acute myeloid leukemia and non-Hodgkin lymphoma. This innovative compound simultaneously inhibits PIM1/2/3 and CDK2/4/6 kinases, disrupting critical downstream signaling pathways that drive tumor cell differentiation and proliferation. 

A first-in-class humanized monoclonal antibody targeting CD38 for the treatment of multiple myeloma (MM) and autoimmune diseases. With FDA IND approval secured, this program addresses an $8B market opportunity with strong global patent protection.

A best-in-class recombinant humanized antibody targeting 4-1BB (CD137) for advanced and metastatic solid tumors. This injectable therapeutic addresses a $6B market opportunity with FDA IND approval and strong global patent protection.

 A breakthrough antibody-drug conjugate (ADC) targeting DLL3 for small cell lung cancer (SCLC) and other neuroendocrine tumors 

 A breakthrough approach in hematologic oncology, simultaneously targeting the FLT3 and CSF1R pathways to address both tumor cells and the immunosuppressive tumor microenvironment. This dual mechanism offers a differentiated therapeutic strategy for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). 

 Polysaccharide Drug Conjugate

 First-in-class, IND-ready, anti-PD-L1 ADC with targeted cytotoxic delivery and immune checkpoint inhibition 

Innovative Platform and Pipeline: Transforming cancer treatment through tumor-specific activation technology. 

 Clinical-stage antisense oligonucleotide (ASO) therapeutic targeting AKT-1, with potential across a range of cancer types.  

 Proprietary CpG-ODN LNP formulation functioning as a TLR9 agonist designed to reinvigorate anti-tumor immunity. 

 A novel anti-PD-L1/B7H3 bispecific antibody-drug conjugate (BsADC, DAR8) engineered to overcome the key limitations of single-target ADCs and IO-refractory disease. By simultaneously engaging two broadly expressed tumor antigens (PD-L1 and B7H3), it delivers potent, selective cytotoxicity, while preserving immune cell integrity and activating immunogenic cell death.